Rilmazafone

The following information was compiled in November 2023 and is subject to change as new research is conducted and as new information becomes available:

Description: Rilmazafone is a benzodiazepine-type drug that has recently emerged in the recreational drug supply. As a prodrug, rilmazafone is converted in the body to the benzodiazepine rilmazolam (below), which is the analyte expected to appear in toxicology specimens; however, standard reference material for rilmazolam is not currently available. Rilmazafone and its metabolites were reported in two fatal intoxications involving the drug in Europe.¹

Sample Source: PA Groundhogs (Pennsylvania)

Sample Appearance: Pills

Pharmacology: The pharmacology of rilmazafone is extensively published in the literature.²

Toxicology: As expected, rilmazafone has not been detected in toxicology cases at the CFSRE.

Drug Materials: Rilmazafone has been detected in two drug materials at the CFSRE.

Demographics / Geographics: Drug materials originated from the state of Pennsylvania.

Legal Status: Rilmazafone is not explicitly scheduled in the United States.

Class:

Benzodiazepine

Appearance:

Pill

Formula:

C21H20Cl2N6O3

MW:

475.3

[M+]:

474

[M+H]+:

475.1047

IUPAC:

5-[[(2-aminoacetyl)amino]methyl]-1-[4-chloro-2-(2-chlorobenzoyl)phenyl]-N,N-dimethyl-1,2,4-triazole-3-carboxamide

Report Date:

November 29, 2023